Response to Duovent of chronic reversible airways obstruction--a controlled trial in general practice.
A controlled trial was carried out in general practice comparing, in two successive 3 week periods, respiratory function in patients with chronic reversible airway obstruction treated, in the first period with their existing metered dose inhaler (MDI) and in the second period with Duovent , an MDI combining anticholinergic and beta2-stimulant agents respectively. One hundred and twenty-two patients were included. Peak expiratory flow rates were increased to a statistically significant degree during the Duovent period and, during this period, there was a significant reduction in day-time cough, night-time wheeze and night wakings . Global ratings by patients and physicians showed that 76% of patients improved with Duovent , and two-thirds of the patients preferred Duovent to their former MDI. Side effects with Duovent were mild, with dry mouth predominating.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001294:Attitude to Health; D001991:Bronchitis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005280:Fenoterol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009241:Ipratropium / Q000009:adverse effects / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate
D001286:Atropine Derivatives; D004338:Drug Combinations; D004983:Ethanolamines; C030809:fenoterol, ipratropium drug combination; D005280:Fenoterol; D009241:Ipratropium